The Institute for Clinical and Economic Review (ICER) on Tuesday, July 9, announced its preliminary list of candidates for reviews in 2020.
According to a press release, the following drugs are among the possible targets for review:
- Luspatercept, Acceleron Pharma;
- Zynteglo, bluebird bio;
- VX-445/tezacaftor/ivacaftor, Vertex Pharmaceuticals;
- Valoctocogene roxaparvovec, BioMarin Pharmaceutical; and
- Lisocabtagene maraleucel, Celgene.
“ICER desires to time reports so that they are released as close to FDA approval as possible,” the press release states. “Due to the eight-month timespan required to conduct each assessment, some of the drugs under consideration have not yet been submitted to the FDA for approval.”
To see the full list of review candidates, click here.